SAGE Therapeutics (SAGE) Receives a New Rating from Oppenheimer

Oppenheimer analyst Jay Olson initiated coverage with a Buy rating on SAGE Therapeutics (NASDAQ: SAGE) today and set a price target of $170. The company’s shares opened today at $127.36.

Olson noted:

“We initiate coverage of SAGE with an Outperform rating and $170 PT, based on our view that SAGE should become a leader in anti-depressants with two drugs in late-stage development: IV brexanolone for Postpartum Depression (PPD) and oral SAGE-217 for PPD and Major Depressive Disorder (MDD). Three near-term catalysts could unlock significant value, especially for SAGE-217, a key contributor to our valuation. We view these catalysts as skewed toward positive outcomes: (1 and 2) brexanolone is well positioned for an upcoming and PDUFA (12/19), in our opinion, based on a favorable risk/benefit ratio in an indication with no FDA- approved therapy; and (3) Ph3 PPD data from the ongoing SAGE-217 trial in 4Q18.”

According to, Olson ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -3.8% and a 40.6% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Eiger Biopharmaceuticals, and Conatus Pharmaceuticals.

Currently, the analyst consensus on SAGE Therapeutics is a Strong Buy with an average price target of $219.67.

See today’s analyst top recommended stocks >>

Based on SAGE Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $90 million and GAAP net loss of $16.98 million. In comparison, last year the company had a GAAP net loss of $73.72 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.